

Efficient Expression of Recombinant Soluble Apoptin in *Escherichia coli* and *Bacillus subtilis*

Sahlan M. Savitri I. K., Prasetyo A.A., Onuma C., Ishikawa S., Malik A. and Ogasawara N.

Abstract—Apoptin, a small protein encoded by chicken anemia virus (CAV), has great attention in last decade because of its ability to induce apoptosis of tumor cells selectively. This protein was expressed as a recombinant protein by employing *Escherichia coli* and *Bacillus subtilis* as hosts for expression. Gateway cloning system was used in this study to clone Apoptin gene, while plasmid destination vectors pOGW and pOXGW were used for expression of apoptin gene in *E. coli* and *B. subtilis*, respectively. In the former plasmid vector IPTG was employed as an inducer for protein expression whereas in the latter xylose, cheaper inducer than IPTG, was employed. A 12 his tag was added to the C-terminal, whilst a Shine Dalgarno (SD) promoter sequence and an ATG start codon were added to the N-terminal region preceding the Apoptin structural gene. The expressed recombinant Apoptin was purified by performing affinity chromatography column of immobilized Ni²⁺. Results from SDS-PAGE show that the recombinant protein was well expressed, and furthermore, the protein was produced in soluble form. We were also able to demonstrate that recombinant Apoptin can also be produced in soluble form by adding cell-penetrating peptide, octaarginine. This soluble recombinant Apoptin open the way to confirm biophysical, biochemical properties and detail mechanism of Apoptin inducing-apoptosis, *in vitro*, and producing recombinant protein apoptin efficiently.

Keywords— apoptin, *Bacillus subtilis*, 12 his tag, soluble protein.

I. INTRODUCTION

Apoptin is a protein of 121 amino acids and 14 kDa which is isolated from chicken anemia virus (CAV). This protein has an ability to induce apoptosis in various human tumors and transformed cells [1-3], and it is potential to be used in medical application for the treatment of cancers because they appear to recognize the process of cancerous normal cell and to induce apoptosis when the process occur [4]. It was reported that apoptin selectively induces apoptosis process in various cancer cell including osteosarcoma,

hepatoma, cholangiocarcinoma, melanoma, colon carcinoma, lung cancer, breast cancer, prostate and cervix cancer and so on, and it has no effect in normal cells [5-6]. Unfortunately, the mechanism of selective apoptin-induced-tumor cell apoptosis are still being understood [6]. One of the reasons is biophysical properties and structure is not elucidated yet causing difficulties to express recombinant protein apoptin in native form [6].

The Apoptin was expressed for the first time as reported by Leliveld and coworkers in bacterial and mammalian cells. They constructed several apoptin recombinant. They fused N-terminal of apoptin with maltose binding protein (MBP) and fused the C-terminal of it with six histidine and were transformed in mammalian and bacterial cells. Unfortunately, the recombinant Apoptin formed insoluble aggregates even tagged with maltose binding protein. To treat insoluble recombinant apoptin, the apoptin resuspended in the buffer containing 6 M urea was refolded in phosphate buffer [7]. Guelen and coworkers, 2004, tried to fuse Apoptin with HIV-1 trans-activator protein (TAT) that have ability to deliver protein across the cell membrane and express it in *Escherichia coli*. Similarly, the recombinant protein formed inclusion body, and then treated by denaturing agent 8 M urea. The urea was removed by through the desalting column [8]. Furthermore, the recombinant Apoptin was expressed as a fusion with more efficient peptide that deliver protein across the cellular membrane, protein transduction domain 4 (PTD4) by Sun *et al.* (2009) and purified it with similar method as Guelen *et al.* [9]. The last, Yan and coworkers (2010) also tagged Apoptin with carcinoembryonic antigen called CAtn and produced inclusion body recombinant protein and was then refolded by treated with denaturing agent, 8 M urea followed by refolding process incubation in the refolding buffer [10].

Here, we present for the first time, soluble recombinant apoptin expressed in *E. coli* and *Bacillus subtilis*. In this study we describe four strategies to obtain native form Apoptin by recombination. In previous report, a His(6)-tag was added at C-terminal of Apoptin, and this did not disturb the apoptosis activity [10], Here we first constructed a 12 × Histidine tagged Apoptin in C-terminal and inserted in pOGW which IPTG -inducing expression vector. Second, to produce Apoptin in large scale, use of cheaper inducer than IPTG would be realistic for application purpose. Thus, we constructed a new destination vector, pOXGW, which can be converted to expression vector in which cloned gene can be induced by xylose. We used SD promoter in both

S. M. and S.I.K are with the Department of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus Depok 16424, Indonesia (corresponding author to provide phone: +62-21-7863516; fax: +62-21-7863515; e-mail: sahlam@che.ui.ac.id).

P. A. A. is Center of Biotechnology and Biodiversity Research and Development, Sebelas Maret University, Jl. Ir. Sutami 36A, Surakarta 57126, Indonesia and Biomedical Laboratory, Faculty of Medicine, Sebelas Maret University, Jl. Ir. Sutami 36A, Surakarta 57126, Indonesia

O. C., I.S and O. N., are with Graduate School of Biological Science, Nara Institute of Science and Technology, 8916-5, Takayama, Ikoma, Nara 630-0192, Japan.

M. A. is with Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok 16424, Indonesia.

constructed by Gateway[®] cloning system [11]. The gene of apoptin was amplified by PCR from pHM6-apoptin and fused with 12 × histidine tag to the C-terminal. We also fused Apoptin gene with octaarginine and 12 × histidine to C-terminus and inserted them to pDONR201 produced pENTR-apoptins (see Fig. 1). Final DNA sequencing of the construction confirmed that the sequences matched with apoptin, 12 histidine and 8 arginine genes (data not shown). Finally, by using LR reactions the expression plasmids was produced.




Fig 1. Schematic illustration of the plasmid construction for the expression of Apoptin. pHM6-apoptin was amplified by two step PCR. The first PCR the primers contain annealing region with apoptin gene, the second PCR extend the first fragments PCR with *attB1* and *attB2*, see material and method for detail description

B. Expression and Purification of Recombinant Apoptin

To study the constructed expression plasmids, first, we transformed pG-apoptin-12his into the *E. coli* strain DH5 α and selected on LB plates containing tetracycline. The selected colony were cultured in 1 litre LB medium, induced by 1 mM IPTG and treated as described above. Previously reported results showed that recombinant protein apoptin produced inclusion bodies. Surprisingly, we found that the apoptin fused with 12×His tag to C-terminal produced in supernatant on lysate buffer without refolding processes. The protein was efficiently purified by immobilized metal ion-affinity chromatography (Ni²⁺-chelating) column. This construction of pG-apoptin-12his should produce a recombinant protein of approximately 16 kDa (about 14 kDa of apoptin and 2 kDa of 12 histidine). As shown in Fig. 2A, the band approximately 36 kDa shifted up with the predicted full-length fusion protein of apoptin-12×his. This phenomena occasionally occur in polyhistidine linked recombinant protein [15]. Second, we also transformed pG-apoptin-12his-8Arg into the *E. coli* cells, and the recombinant protein was produced in soluble form and SDS-PAGE analysis shows the band shifted up with the prediction (Fig. 2B).

To produce apoptin in large scale, use of cheaper inducer than IPTG would be realistic for application purpose. Thus, we constructed a new destination vector, pOXGW, which can

be converted to expression vector in which cloned gene can be induced by xylose. To construct pOXGW, xylose-controllable expression cassette containing *xylA* promoter and *xylR* (repressor for *xylA* promoter) derived from *Bacillus megaterium* was amplified from pX plasmid with *xylR*-F-*XhoI* and *xylR*-R-*SphI* primers, which contain *XhoI* and *SphI* sites at the 5' ends respectively [12]. Then, we inserted apoptin gene to it, which produced pXG-apoptin-12his and pXG-apoptin-12his-8arg. For confirming our constructed plasmid, we transformed pXG-apoptin-12his-8arg into *B. subtilis* cells and cultured in 1 litre LB medium, induced by xylose and treated as described above. The results shows that 1% xylose could control expression system in *B. subtilis*, and produce soluble apoptin similar with *E. coli* IPTG-induced expression system. SDS-PAGE analysis also shows the band shifted up with the prediction Fig. 3.




Fig 2. SDS-PAGE analysis of the expression of apoptin-12×His (a) and apoptin-12×His-8×Arg (b) in *E. coli*. M1: Molecular mass marker 1 (from bottom to top: 10, 15, 20, 30, 40, 60, 80, 100, 150, 200 kDa); M2: Molecular mass marker 2 (from bottom to top: 8, 15, 18, 23, 31, 36, 44, 55, 75, 105, 150 kDa); Lane 1: supernatant of cell lysate; Lane 2: pellet of cell lysate; Lane 3: eluted fraction containing apoptin-12×His (a) and apoptin-12×His-8×Arg (b). The arrow indicates the band corresponding to the Apoptin.

In this work we presented for the first time the soluble recombinant apoptins expressed in *E. coli* and *B. subtilis*, without resuspending and refolding processes. The results are different from other resulting that fused apoptin with six histidine, MBP, TAT, PTD4 and carcinoembryonic antigen, fusing apoptin with 12 histidine improve the solubility of apoptin in buffer. Furthermore, the expression system we developed is efficient because of the xylose-dependent system and one step purification.




Fig 3. SDS-PAGE analysis of the expression of apoptin-12×His-8×Arg (b) in *B. subtilis*. M: Molecular mass marker (from bottom to top: 10, 15, 20, 30, 40, 60, 80,100, 150, 200 kDa); Lane 1 and 2: supernatant of cell lysate; Lane 3: eluted fraction containing apoptin-12×His-8×Arg. The arrow indicates the band corresponding to the Apoptin

- [7] Leliveld SR, Zhang YH, Rohn JL, Noteborn MH, Abrahams JP (2003) Apoptin induces tumor-specific apoptosis as a globular multimer. *J Biol Chem* 278 (11):9042-9051
- [8] Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M (2004) TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. *Oncogene* 23 (5):1153-1165.
- [9] Sun J, Yan Y, Wang XT, Liu XW, Peng DJ, Wang M, Tian J, Zong YQ, Zhang YH, Noteborn MH, Qu S (2009) PTD4-apoptin protein therapy inhibits tumor growth in vivo. *Int J Cancer* 124 (12):2973-2981
- [10] Yan L, Xiangwei M, Xiao L, Peng G, Chang L, Mingyao T, Encheng Y, Xiaohong X, Peng J, Shifu K, Zhongmei W, Ningyi J (2010) Construction, expression and characterization of a dual cancer-specific fusion protein targeting carcinoembryonic antigen in intestinal carcinomas. *Protein Expr Purif* 69 (1):120-125
- [11] Borges JP, Culierrier R, Aldon D, Barre A, Benoist H, Saurel O, Milon A, Didier A, Rouge P (2010) GATEWAY technology and *E. coli* recombinant system produce a properly folded and functional recombinant allergen of the lipid transfer protein of apple (*Mal d 3*). *Protein Expr Purif* 70 (2):277-282
- [12] Kim L, Mogk A, Schumann W (1996) A xylose-inducible *Bacillus subtilis* integration vector and its application. *Gene* 181 (1-2):71-76
- [13] Ishikawa S, Kawai Y, Hiramatsu K, Kuwano M, Ogasawara N (2006) A new FtsZ-interacting protein, YlmF, complements the activity of FtsA during progression of cell division in *Bacillus subtilis*. *Mol Microbiol* 60 (6):1364-1380
- [14] Prasetyo AA, Kamahora T, Kuroishi A, Murakami K, Hino S (2009) Replication of chicken anemia virus (CAV) requires apoptin and is complemented by VP3 of human torque teno virus (TTV). *Virology* 385 (1):85-92

IV. CONCLUSION

A conclusion this soluble recombinant apoptins produced in the present work, open the way to confirm biophysical, biochemical characterization and study detail mechanism of apoptin inducing-apoptosis, *in vitro*.

ACKNOWLEDGMENT

This work was supported by Japan Society for The Promotion of Science Program in the NAIST advanced Biotechnology Training Program towards Understanding, Preservation and Utilization of Indonesian Bioresources in Nara, Japan and funded by Universitas Indonesia. Hibah Riset Madya 2012 with number of contract 1913/H2.R12.1/HKP.05.00/2012.

REFERENCES

- [1] Wagstaff KM, Jans DA (2009) Nuclear drug delivery to target tumour cells. *Eur J Pharmacol* 625 (1-3):174-180
- [2] Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, Backendorf C, Quax PH, Van der Eb AJ, Noteborn MH (1997) Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. *Proc Natl Acad Sci U S A* 94 (11):5843-5847
- [3] Argiris K, Panethymitaki C, Tavassoli M (2011) Naturally occurring, tumor-specific, therapeutic proteins. *Exp Biol Med* (Maywood) 236 (5):524-536
- [4] Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann F, Schulze-Osthoff K (2009) Apoptin, a tumor-selective killer. *Biochim Biophys Acta* 1793 (8):1335-1342
- [5] Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H (2011) Towards novel paradigms for cancer therapy. *Oncogene* 30 (1):1-20
- [6] Zhou S, Zhang M, Zhang J, Shen H, Tangsakak E, Wang J (2011) Mechanisms of Apoptin-induced cell death. *Med Oncol*.